Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions

Tuesday, March 7, 2017 1 min read

Key Takeaway: Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions

Full Press Release Details

Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions.